Actively Recruiting
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery
Led by Massachusetts General Hospital · Updated on 2026-05-06
80
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The proposed R21 project will attempt to further develop a novel intervention for posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in normal humans has shown that when a stable, consolidated memory is reactivated (i.e., retrieved) under appropriate conditions, it reverts to an unstable state, a process referred to herein as deconsolidation. In such a state, the memory is susceptible to the action of various "amnestic" agents that may inhibit its reconsolidation, thereby weakening it. The β-adrenergic blocker propranolol (PPNL) possesses such amnestic properties. More recent research has found that in order to initiate deconsolidation, there must be a prediction error, or mismatch, between what is expected and what occurs when the memory is reactivated. Prior placebo-controlled, randomized clinical trials (PBO-RCT) from our laboratory have found that when propranolol is administered concomitant with the reactivation of a psychologically traumatic memory, the memory is weakened, as revealed by subsequent lower physiological (heart rate, skin conductance, facial electromyogram) responding during script-driven mental imagery. Clinical applicability was evaluated in a PBO-RCT, in which PTSD participants receiving propranolol underwent six weekly sessions of 10-20 min of "standard" (STD) traumatic memory reactivation stimulated by reading a narrative. At post-treatment, these participants showed a greater reduction of PTSD symptoms compared to participants who had taken PBO. The goal of the proposed study is to test whether intentionally incorporating innovative mismatch (MM) into traumatic memory reactivation can improve upon physiological responding during script-driven mental imagery. Participants will be randomized to one of 2 treatment arms: STD/PPNL and MM/PPNL. A baseline assessment will measure psychophysiological responsivity to script-driven mental imagery (target measure). PPNL will be administered 90-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions. In the MM condition, a different, unexpected mismatch (e.g., singing the narrative) will be incorporated into the reactivation. In the STD condition, the participant will read the narrative the same way each time. The focus of the R21 proposal will be to assess whether the MM/PPNL group shows lower subsequent physiological responses than the STD/PPNL group
CONDITIONS
Official Title
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 18 to 65 years
- Experienced a traumatic event meeting DSM-5 PTSD Criterion A
- PCL-5 score greater than 33
- Must meet psychophysiological reactivity criteria during baseline script-driven imagery testing
- Able to understand English and provide informed consent
You will not qualify if you...
- Basal sitting or standing systolic blood pressure below 90/60 mm Hg or basal heart rate below 50 BPM
- Medical conditions contraindicating propranolol (e.g., congestive heart failure, heart block, insulin-requiring diabetes, chronic bronchitis, emphysema, or certain asthma cases)
- Previous adverse reaction to or non-compliance with beta-blockers
- Current use of medications with potential dangerous interaction with propranolol (e.g., anti-hypertensives, antiarrhythmics, benzodiazepines)
- Presence of drugs of abuse or alcohol at initial assessment
- Pregnancy or breastfeeding
- Contraindicating psychiatric conditions such as psychotic disorders, bipolar disorder, melancholic depression, active substance use disorder, or suicidality
- Initiation or change in psychotropic medication within the previous two months unless stable and clinically approved
- Current participation in psychotherapy other than supportive unless clinically urgent
- Inability to understand study procedures, risks, or provide informed consent
- Lack of English language comprehension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital Home Base Program
Charlestown, Massachusetts, United States, 02129
Actively Recruiting
Research Team
J
James Cappellucci
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here